GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immunoclin Corp (GREY:IMCL) » Definitions » Net Income From Continuing Operations

Immunoclin (Immunoclin) Net Income From Continuing Operations : $-7.98 Mil (TTM As of Oct. 2014)


View and export this data going back to 2012. Start your Free Trial

What is Immunoclin Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Immunoclin's net income from continuing operations for the three months ended in Oct. 2014 was $-6.12 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Oct. 2014 was $-7.98 Mil.

Immunoclin Net Income From Continuing Operations Historical Data

The historical data trend for Immunoclin's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immunoclin Net Income From Continuing Operations Chart

Immunoclin Annual Data
Trend Feb12 Jan13 Jan14
Net Income From Continuing Operations
-0.09 -0.07 -12.98

Immunoclin Quarterly Data
May11 Aug11 Nov11 Feb12 May12 Aug12 Nov12 Feb13 May13 Aug13 Nov13 Apr14 Jul14 Oct14
Net Income From Continuing Operations Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.07 -0.07 -0.79 -1.00 -6.12

Immunoclin Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Oct. 2014 adds up the quarterly data reported by the company within the most recent 12 months, which was $-7.98 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Immunoclin (Immunoclin) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immunoclin Corp (GREY:IMCL) » Definitions » Net Income From Continuing Operations
Comparable Companies
BOM:506128 ASX:ATX OSTO:ANNX IMUN ASX:FIJ ASX:FTT ATRX TSXV:THRM WAR:BLR FNAM ASX:NC6 XCNQ:VP ENLV ASX:RAC VODG TSXV:MFS OSTO:A1M XSAT:CLINE B ASX:MEB XCNQ:LILY
Traded in Other Exchanges
N/A
Address
9107 Wilshire Boulevard, Suite 450, Beverly Hills, CA, USA, 90210
Website
http://www.immunoclin.com
Immunoclin Corp is engaged in immunology research and development skill to serve the pharmaceutical, biotechnology and food industries, providing comprehensive, clinical and basic science research expertise at a commercial scale and quality.

Immunoclin (Immunoclin) Headlines

No Headlines